Esther Landhuis

Optometrists are lobbying for more leeway to treat patients — and physicians' groups are pushing back. But it's more than a turf war, both sides say, as they explain why patients' vision is at stake.

Philanthropies are funding studies of cheap, existing meds like fluvoxamine as treatments. But early hype about hydroxychloroquine and other drugs leaves researchers leery of hasty conclusions.